Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Form 144 notice for Ionis Pharmaceuticals (IONS) reports a proposed sale of 20,000 shares of common stock through Stifel Nicolaus & Company on 09/02/2025 on Nasdaq with an aggregate market value of $1,018,296. The filing states there are 159,391,229 shares outstanding.
The securities to be sold were acquired as restricted stock units on 01/15/2017 totaling 78,321 shares, with payment noted as cash. The filing also discloses a prior sale by Lynne Parshall of 5,000 shares on 08/06/2025 for gross proceeds of $209,646. The notice includes the standard representation that the seller has no undisclosed material information.
Form 144 notice for Ionis Pharmaceuticals (IONS) reports a proposed sale of 20,000 shares of common stock through Stifel Nicolaus & Company on 09/02/2025 on Nasdaq with an aggregate market value of $1,018,296. The filing states there are 159,391,229 shares outstanding.
The securities to be sold were acquired as restricted stock units on 01/15/2017 totaling 78,321 shares, with payment noted as cash. The filing also discloses a prior sale by Lynne Parshall of 5,000 shares on 08/06/2025 for gross proceeds of $209,646. The notice includes the standard representation that the seller has no undisclosed material information.
Ionis Pharmaceuticals reported positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in severe hypertriglyceridemia (sHTG). Across nearly 1,100 patients required to remain on standard-of-care lipid-lowering therapy, olezarsen produced highly statistically significant, placebo-adjusted mean reductions in fasting triglycerides of up to 72% and a highly statistically significant 85% reduction in acute pancreatitis events. Both 80 mg and 50 mg monthly doses met the primary endpoint at six months with strong p-values (p<0.0001), and the company described safety and tolerability as favorable.
Ionis Pharmaceuticals reported positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in severe hypertriglyceridemia (sHTG). Across nearly 1,100 patients required to remain on standard-of-care lipid-lowering therapy, olezarsen produced highly statistically significant, placebo-adjusted mean reductions in fasting triglycerides of up to 72% and a highly statistically significant 85% reduction in acute pancreatitis events. Both 80 mg and 50 mg monthly doses met the primary endpoint at six months with strong p-values (p<0.0001), and the company described safety and tolerability as favorable.
Ionis Pharmaceuticals Form 144 notice: A holder intends to sell 1,427 shares of Ionis common stock through Insight Securities on the NYSE. The shares were acquired as compensation from Ionis on 08/22/2025 and the planned sale date is listed as 08/22/2025. The filing reports no shares sold in the past three months by the seller. The filing states the seller represents they have no undisclosed material adverse information about the issuer.
Allene M. Diaz, a director of Ionis Pharmaceuticals (IONS), reported the sale of 1,427 shares of common stock on 08/22/2025 at a weighted-average price of $42.5278 per share, reducing her direct holdings to 18,368 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted May 3, 2023, and the filing notes the shares were sold in multiple transactions at prices ranging $42.30 to $42.75. The Form 4 was signed by an attorney-in-fact on 08/26/2025.
Ionis Pharmaceuticals announced that the FDA has approved DAWNZERA (donidalorsen) to prevent hereditary angioedema (HAE) attacks in adults and children 12 and older. DAWNZERA is described as the first and only RNA-targeted medicine approved for HAE, given as an 80 mg self-administered subcutaneous autoinjector every four or eight weeks.
The approval is based on the Phase 3 OASIS-HAE study, where DAWNZERA given every four weeks reduced monthly HAE attack rates by 81% versus placebo over 24 weeks, and by 87% from the second dose. It also cut moderate-to-severe attacks by about 90%. In the OASISplus extension, DAWNZERA showed a 94% mean attack rate reduction from baseline across dosing groups after one year.
In patients switching from other prophylactic treatments, DAWNZERA lowered mean attack rates by 62% over 16 weeks, and 84% of surveyed patients preferred it, citing better disease control and easier administration. The most common side effects were injection site reactions, upper and urinary tract infections, and abdominal discomfort.
C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), reported option exercise and share sale transactions on 08/18/2025. He was granted or exercised a non-qualified stock option with a $32.60 exercise price covering 10,000 shares exercisable from 01/03/2023 and expiring 01/02/2032, which increased his direct common stock holdings to 103,466 shares. On the same date, he sold 10,000 shares pursuant to a Rule 10b5-1 trading plan adopted May 13, 2025, for a weighted average price of $43.9776 per share (sales occurred at prices between $43.75 and $44.25). Following the sale, his reported direct common stock ownership was 93,466 shares. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on behalf of Mr. Bennett.
Ionis Pharmaceuticals Form 144 filing summary — This notice reports a proposed sale of 16,000 shares of the issuer's common stock through Stifel Nicolaus & Company, Inc. with an aggregate market value of $703,642.00. The sale is scheduled approximately for 08/18/2025 on Nasdaq. The filing lists prior acquisitions underlying the shares: an option exercise on 01/03/2022 totaling 28,869 shares, restricted stock units granted on 01/15/2017 for 7,537 shares, and restricted stock units on 01/15/2016 for 6,373 shares. The table for sales during the past three months shows Nothing to Report. Several identifying fields (filer CIK/CCC and the named person for whose account the sale is proposed) are not provided in the content.
Ionis Pharmaceuticals director B. Lynne Parshall sold 5,000 shares of Ionis common stock on 08/06/2025 under a pre-established Rule 10b5-1 trading plan adopted May 6, 2025. The filings report two sales: 4,600 shares at a weighted-average price of $41.8685 (individual trade prices ranged from $41.50 to $42.36) and 400 shares at a weighted-average price of $42.6275 (individual trade prices ranged from $42.56 to $42.83). Following the reported transactions, the Form 4 shows beneficial ownership figures of 86,744 shares and 86,344 shares respectively. The reporting person is identified as a director and the sales were executed pursuant to the disclosed trading plan.
Filing type: Form 144 notice for Ionis Pharmaceuticals, Inc. (IONS).
Proposed sale: 10,000 shares of Common Stock through Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO) on 08/06/2025, with an aggregate market value of $419,292.00. The filing lists 159,391,229 shares outstanding.
Acquisition details: 42,223 shares were acquired as Restricted Stock Units on 01/15/2017; payment: Cash. The filing shows "Nothing to Report" for securities sold in the past 3 months. The filer identity/CIK and submission contact fields are not provided in the form content.